IP Library Granted Patent US 12,097,184
Granted Patent B2
US 12,097,184 · App. 18/326,480 · Granted Sep 24, 2024

Formulations of psilocin that have enhanced stability

Inventors: Robert Barrow (Madison, WI); Peter Mack (Chapel Hill, NC); Stephen Schneider (Raleigh, NC); Jon Schroeder (Madison, WI); Gerald S. Jones (Norwood, MA)
Assignee: Mind Medicine, Inc.
A61K31/4045
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,097,184
App. No.
18/326,480
Granted
Sep 24, 2024
Kind
B2
Abstract

A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual and treating the disease or condition.

Claims (4)

1. A composition of psilocin that is stable consisting of:

a pharmaceutical salt of psilocin that provides enhanced stability wherein said salt is formed between psilocin and an anion chosen from the group consisting of besylate and lactate; and

a pharmaceutically acceptable carrier, wherein enhanced stability includes being shelf-stable, being stable in cold storage, and being stable in storage under inert conditions.

2. The composition of claim 1 , wherein enhanced stability includes being shelf-stable, being stable in cold storage, and being stable in storage under inert conditions, wherein said composition is in a formulation chosen from the group consisting of a liquid dosage form and a solid dosage form, and wherein said composition is in a formulation chosen from the group consisting of a liposome formulation and a nanoparticle formulation.

Assignments (2)
CHANGE OF NAME Recorded Jan 26, 2026
From: MIND MEDICINE, INC.
To: DEFINIUM THERAPEUTICS US, INC.
Reel/Frame 074489/0176 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2023
From: BARROW, ROBERT; MACK, PETER; SCHNEIDER, STEPHEN; SCHROEDER, JON; JONES, GERALD S., JR
To: MIND MEDICINE, INC.
Reel/Frame 063811/0751 →
Continuity (5)
Continuation 17883509 · Aug 8, 2022
Continuation In Part 17687568 · Mar 4, 2022
Provisional Application 63184691 · May 5, 2021
Provisional Application 63157682 · Mar 6, 2021
Related Publication 20230285359A1 · Sep 14, 2023